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Abstract
Inorganic arsenic (iAs) is an environmental toxicant and human carcinogen. The enzymatic
methylation of iAs that is catalyzed by arsenic (+3 oxidation state)-methyltransferase (AS3MT)
generates reactive methylated intermediates that contribute to the toxic and carcinogenic effects of
iAs. We have shown that clonal human urothelial cells (UROtsa/F35) that express rat AS3MT and
methylate iAs are more susceptible to acute toxicity of arsenite (iAsIII) than parental UROtsa cells
that do not express AS3MT and do not methylate iAs. The current work examines transcriptional
changes associated with AS3MT expression and identifies specific categories of genes expressed
in UROtsa and UROtsa/F35 cells in response to a 24-h exposure to 1 or 50 μM iAsIII. Here, the
expression of 21,073 genes was assessed using Agilent Human 1A(V2) arrays. Venn analysis
showed marked concentration-dependent differences between gene expression patterns in UROtsa
and UROTsa/F35 cells exposed to iAsIII. Among 134 genes altered by exposure to subtoxic 1 μM
iAsIII, only 14 were shared by both cell lines. Exposure to cytotoxic 50 μM iAsIII uniquely altered
1389 genes in UROtsa/F35 and 649 genes in UROtsa cells; 5033 altered genes were associated
with the chemical alone. In UROtsa, but not UROtsa/F35 cells exposure to 1 μM iAsIII altered
expression of genes associated with cell adhesion. In contrast, expression of genes involved in cell
cycle regulation was significantly altered in UROtsa/F35 cells at this exposure level. At 50 μM
iAsIII, pathways regulating cell cycle, cell death, transcription, and metabolism were affected in
both cell lines. However, only Urotsa/F35 cells showed numerous G-protein and kinase pathway
alterations as well as alterations in pathways involved in cell growth and differentiation. These
data link the AS3MT-catalyzed methylation of iAs to specific genomic responses in human cells
exposed to iAsIII. Further analysis of these responses will help to characterize the role of AS3MT-
catalyzed methylation in modulation of iAsIII toxicity.
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The enzymatic methylation of inorganic arsenic (iAs) is the major pathway for metabolism
of iAs in humans and in many other mammalian species.1,2 Arsenic (+3 oxidation state)-
methyltransferase (AS3MT) is the key enzyme in this pathway.3,4 The methylation of iAs by
human AS3MT yields methylarsenic (MAs) and dimethylarsenic (DMAs) metabolites that
contain arsenic (As) in either +5 oxidation state (AsV) or +3 oxidation state (AsIII).5,6 The
toxicity of each of these metabolites differs significantly from toxicities of iAs species. In
general, iAs species, for example, arsenite (iAsIII) or arsenate (iAsV), are an order of
magnitude more toxic than methylated pentavalent arsenicals (MAsV or DMAsV), but less
toxic than methylated trivalent arsenicals (MAsIII or DMAsIII).7–9 Thus, the adverse
outcomes of acute or chronic exposures to iAs depend in part on the amounts and the ratios
of various metabolites produced in the AS3MT-catalyzed reactions and retained in target
tissues.
AS3MT is expressed in rat and human hepatocytes that are efficient methylators of iAs,10
but not in SV-40 transformed normal human urothelial (UROtsa) cells that do not methylate
iAs.11 To examine the role of AS3MT-catalyzed methylation in the toxicity of iAs exposure,
we have recently created a genetically modified UROtsa cell line (UROtsa/F35) that
expresses rat AS3MT and methylates iAs.11 When exposed to iAsIII UROtsa/F35 cells
produce MAsIII, MAsV, DMAsIII, and DMAsV. Our previous work has shown that UROtsa/
F35 cells are more sensitive than the parent UROtsa cells to acute toxicity of iAsIII.11
Notably, when exposed to iAsIII, UROtsa/F35 cells retained less As than UROtsa cells.
However, a significant portion of As retained by UROtsa/F35 cells is represented by
methylated metabolites of iAsIII. These metabolites are absent in the parent UROtsa cells
that lack AS3MT activity. Thus, the increased susceptibility of UROtsa/F35 cells to iAsIII is
associated with the production and cellular retention of methylated arsenicals.
The goal of the present study was to compare gene expression patterns in UROtsa and
UROtsa/F35 cells before and after exposure to subtoxic or toxic concentration of iAsIII and
to identify specific transcriptional responses associated with the expression of AS3MT and
with the production of methylated arsenicals in UROtsa/F35 cells. Because this study was
designed as a pilot study with limited number of samples, we elected to examine the
resulting transcriptional results on a cellular pathway level as opposed investigating
individual genes. Our data show significant quantitative and qualitative differences between
the transcriptional profiles in UROtsa and UROtsa/F35 cells exposed to either subtoxic or
toxic concentration of iAsIII. The character of genomic responses specific for UROtsa/F35
cells suggest that at low exposure levels, the AS3MT-catalyzed methylation of iAs is
associated with changes in pathways regulating cell cycle and nucleotide metabolism. At
high exposure levels, the methylation of iAs affects mainly G-protein- and protein kinase-
mediated pathways, as well as pathways involved in cell growth and differentiation. Taken
together, these results show that genomic responses would differ in cells or tissues with
different capacities to methylate iAs and in cells or tissues exposed to different iAs
metabolites. This work provides additional evidence that the enzymatic methylation of iAs
plays a key role in determining the adverse outcomes associated with either acute or chronic
exposures to iAs.
Material and methods
Cell lines and treatments
UROtsa cells, which are SV-40 transformed normal human urothelial cells, were obtained
from Dr Unimye (Department of Urology, West Virginia University). The clonal UROtsa/
F35 cell line expressing rat AS3MT was created from the parent UROtsa cell line, using a
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retroviral pLEGFP-N1 gene delivery system.11 Both UROtsa and UROtsa/F35 cells were
cultured in MEM (GIBCO BRL, Grand Island, New York, USA) medium supplemented
with 10% FBS (GIBCO BRL), penicillin (50 U/ml, Sigma, St. Louis, Missouri, USA), and
streptomycin (50 μg/ml, Sigma). Cells were cultured in 60-mm diameter culture dishes
(Falcon, Becton Dickinson Labware, Lincoln Park, New Jersey, USA) at 37 °C in a
humidified incubator in a 95% air/5% CO2 atmosphere. Confluent cell cultures were serum
starved for 16 h prior to exposure to iAsIII. To characterize the metabolic activity of UROtsa
and UROtsa/F35 cultures, serum starved cells were incubated with 1 or 50 μM [73As]iAsIII
for 24 h in a cell culture incubator as previously described.11 Radiolabeled metabolites were
then analyzed in CuCl-treated cell lysates and cell culture media by thin-layer
chromatography (TLC).12 Both cell lysate and media were oxidized by hydrogen peroxide
before TLC analysis. This method determines total iAs (iAsIII + iAsV), total MAs (MAsIII +
MAsV), and total DMAs (DMAsIII + DMAsV). For microarray analysis, both UROtsa and
UROtsa/F35 cells were exposed for 24 h to 1 or 50 μM of non-radioactive iAsIII, sodium
salt (Sigma).
RNA isolation, microarray hybridization, and quality control
The expression of 21,073 genes was assessed in UROtsa and UROtsa/F35 cells before and
after exposure to iAsIII, using Agilent Human 1A(V2) arrays (Agilent Technologies, Palo
Alto, California, USA). Total RNA for the microarray analysis was isolated using TRIzol
(Invitrogen Life Technologies, Inc., Carlsbad, California, USA), followed by purification
and DNase-I digestion on RNeasy columns (Qiagen, Valencia, California, USA). Quality of
the isolated RNA was assessed by Agilent 2100 Bioanalyzer (Agilent Technologies). Total
RNA was amplified using the Agilent Low RNA Input Fluorescent Linear Amplification
Kit. The cyanine (Cy)3- and Cy5-labeled cRNA were produced from 500 ng of total RNA,
following the manufacturer’s protocol. For each two-color comparison, 750 ng each of Cy3-
and Cy5-labeled cRNA was mixed and fragmented using the Agilent In Situ Hybridization
Kit protocol (Agilent Technologies). Hybridization of cRNA targets was carried out on the
Agilent human 22K 60-mer oligo microarray platform for 17 h at 60 °C in a rotating
hybridization oven. Slides were washed according to the manufacturer’s protocol and
scanned with an Agilent Technologies DNA Microarray Scanner. Data were generated using
the Agilent Feature Extraction software (version 7.5), employing defaults for all parameters.
Two hybridizations, which include a fluor reversal, were performed for each RNA sample
from each treatment group.
Data analysis
The goal of the microarray analysis was to characterize differences between the gene
expression patterns in UROtsa cells that cannot methylate iAs and in UROtsa/F35 cells that
are capable of iAs methylation before and after exposure to a subtoxic (1 μM) or toxic (50
μM) concentration of iAsIII. To achieve this goal, we first perform a rigorous statistical filter
to find differentially expressed genes (DEGs) for each exposure group. A Venn analysis was
then used to dissect out groups of genes associated with each condition. To identify affected
pathways, these groups of genes were mapped to the MetaCore pathway database (GeneGo,
(St. Joseph, MI) http://www.genego.com/). The MetaCore analysis identified functional
links between differentially expressed genes associated with each condition. Results of this
analysis were displayed in graphic form to answer the question: is there a pathway
distribution more characteristic for one condition versus another?
Rosetta Resolver—Images and GEML (gene expression markup language) files,
including error and P-values, were exported from the Agilent Feature Extraction software
and uploaded into the Rosetta Resolver system (version 4.0, build 4.0.1.0.7.RSPLIT)
(Rosetta Biosoftware, Kirkland, Washington, USA). We combined the resultant ratio
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profiles. Intensity plots were generated for each ratio experiment, and genes were considered
“signature genes” if the P-value was <0.001. Data were analyzed using the Rosetta Resolver
gene expression data analysis system (Rosetta Biosoftware). In Resolver, spots that are
flagged during data acquisition by the Genepix software are not included in the analysis. In
addition, if for a given spot intensities in both channels are below zero after background
subtraction, the data are excluded from further analysis. Additional data processing in this
system consists of error correction and calculation of a P-value of differential expression
using the intensity-error estimation from the .gpr file. Error correction consists of a
simplified version of the algorithm described by Schadt et al.,14 in which a piecewise linear
function replaces smoothing splines to fit and correct intensity non-linearity. Calculation of
P-values consists of a statistic that combines additive and multiplicative error components in
both channels of a two-colored experiment. The resultant ratio profiles (i.e., two-channel,
error processed microarray scans) were combined into ratio experiments in the Resolver
system as described in reference 13. Within the Resolver system, we performed the analysis
at the so-called sequence level. Specifically, when there are multiple data points for the
same gene in the same hybridization, such data are combined. When combining data, it is
assumed that the ratio measurement with the lowest overall error is closest to the true value
for that sequence, and weights are constructed such that the feature or reporter with the
lowest error is given the greatest weight.14
MetaCore GENEGO analysis—We further analyzed the signature genes with MetaCore
GeneGO Systems Biology Analysis Software®, a web-delivered application that enables
biologists to discover, visualize, and explore relevant networks significant to their
experimental results, such as gene expression array data sets. A data set containing gene
identifiers and their corresponding expression values such as fold-changes and P-values was
uploaded as a tab-delimited text file. Each gene identifier was mapped to its corresponding
gene object in the MetaCore® Knowledge Base. A fold change cutoff of 1.5-fold and P <
0.001 was set to identify genes whose expression was differentially regulated. These genes,
called “focus genes,” were then used as the starting point for generating biological networks.
To start building networks, the application queries the Ingenuity Pathways Knowledge Base
for interactions between focus genes and all other gene objects stored in the knowledge base,
and then generates a set of maps and networks. For significance, a hypergeometric
distribution is used to compute a map or network P-value, the number of genes for each map
as well as the numbers of genes in your submitted list, and a percentage for the map. The
score is derived from a P-value and indicates the likelihood of the genes in a network being
found together because of random chance. Other pathway mapping softwares were used to
visualize significant pathways including DAVID/EASE (http://david.niaid.nih.gov/david/
ease.htm) and Ingenuity® Pathway Analysis (Mountain View, California, USA; http://
www.ingenuity.com/index.html).
DAVID Bioinformatic Resources 2006—Using a gene list derived from Venn analysis,
we mapped genes passing the filter to DAVID Functional analysis (National Institute of
Allergy and Infectious Diseases; http://david.abcc.ncifcrf.gov/gene2gene.jsp) to classify the
genes on this list into functional related gene groups.
Statistics—For the Metacore GeneGO Analysis, we used a Fisher’s exact test to calculate
a P-value to determine the probability that the biological function assigned to that network
could be explained by chance alone. The level of significance was set at P < 0.05 in all
cases.
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Metabolic characteristics of UROtsa and Urotsa/F35 cells
iAs was the only As species detected in cell lysates and media from UROtsa cultures
exposed for 24 h to 1 or 50 μM [73As]iAsIII (Figures 1 and 2); cells contained 4% and 8% of
total 73As in culture, respectively. In contrast, UROtsa/F35 cells methylated [73As]iAsIII to
radiolabeled MAs and DMAs. In UROtsa/F35 cultures exposed to 1 μM [73As]iAsIII, MAs
and DMAs accounted for 3% and 73% of 73As retained in cells and for <0.1% and 25%
of 73As in medium. In UROtsa/F35 cultures exposed to 50 μM [73As]iAsIII, MAs was the
major methylated metabolite representing 28% of 73As retained in cells and 14% of 73As in
medium. In UROtsa/F35 cultures exposed to 1 and 50 μM [73As]iAsIII, cells contained 9%
and 6% of total 73As, respectively.
Principal component and Venn analyses
Principal component analysis was performed to capture the variability in gene expression
space by reducing the high dimensionality of the expression data to two or three
components. Results are shown in Figure 3. At 1 μM iAsIII exposure level, UROtsa/F35
cells and UROtsa cells showed similarity to each other. However these cells exposed to 1
μM AsIII differ significantly from cells exposed to 50 μM iAsIII. In contrast, at the 50 μM
iAsIII exposure, UROtsa/F35 cells were distinct from the UROtsa cells. Gene lists were
generated in Rosetta Resolver for each condition, including UROtsa/F35 cells at 1 μM or 50
μM iAsIII, and UROtsa cells at 1 μM or 50 μM iAsIII. Venn analysis (figures 4A and 4B)
showed that exposure to 1 μM iAsIII uniquely altered expression of 96 genes in UROtsa
cells, but only 24 genes in methylating Urotsa/F35 cells. Fourteen genes were altered in both
cell lines. In contrast, exposure to 50 μM iAsIII had a greater impact on gene expression in
Urotsa/F35 cells, changing uniquely expression of 1389 genes as compared to 649 genes in
UROtsa. Changes in expression of 5033 genes were shared by both cell lines.
Cell line-specific pathway effects at 1 and 50 μM iAsIII
Venn analysis gene lists were mapped to evaluate effects of the exposures on specific
pathways. Table 1a shows that, in UROtsa cells exposed to the subtoxic concentration of 1
μM iAsIII, affected mainly pathways regulating cell adhesion and carbohydrate metabolism.
In comparison, pathways regulating cell cycle were altered in UROtsa/F35 cells at this
exposure level (Table 1b). In general, the number of pathways affected by exposure to 1 μM
iAsIII was relatively small (5–7) for either cell line. In contrast, the number of pathways
altered by the cytotoxic concentration of 50 μM iAsIII was significantly greater: 12 in
UROtsa and 37 in UROtsa/F35 cells (Table 2a,b). UROtsa and UROtsa/F35 exposed to 50
μM iAsIII shared some similarity in functional gene categories including cell death,
transcription, and kinases; however, there were no common pathways altered in both cell
lines. Pathways altered in UROtsa cells were characterized by the following categories: cell
cycle, cell death, regulation of transcription, and metabolic pathways. Pathways altered in
the UROtsa/F35 cells involved cell adhesion, cell death, growth and differentiation, immune
response, transcription, G-protein signaling, and metabolism.
Effects associated with iAsIII independent of cell line
The Venn unions for the exposures to 1 μM iAsIII (Figure 4A) and 50 μM iAsIII (Figure 4B)
contained 14 and 5033 genes, respectively. These gene lists were mapped to identify which
pathway changes were specifically associated with the iAsIII exposure. Exposure to 1 μM
iAsIII had a minimal effect, affecting only 10 pathways with only a few genes altered per
pathway (Table 3a). Cell adhesion, growth and differentiation, and metabolism were the
affected gene categories. However, exposure to 50 μM iAsIII produced a marked increase in
Hester et al. Page 5













number of altered pathways with the percentage of pathway coverage ranging from 26 to
78% of genes (Table 3b). The pathways involved in cell cycle regulation and cell death and
apoptosis were among the most affected. Notably, some of altered gene categories were
similar for both exposure levels. However, at 50 μM iAsIII the numbers of altered pathways
within each gene category (e.g., cycle control, growth and death, or nucleotide metabolism)
were much greater than at 1 μM level.
Changes in pathway distribution
The 10 most significantly altered pathways for each experimental condition (Tables 1 and 2)
were categorized by function. Results were displayed graphically to assess whether there
was a characteristic distribution signature of significantly altered pathways associated with
each condition, including UROtsa-50 μM iAsIII, UROtsa/F35-50 μM iAsIII, UROtsa-1 μM
iAsIII, and UROtsa/F35-1 μM iAsIII (Figure 5). Changes in the pathways regulating
metabolism and cell adhesion were characteristic for UROtsa cells exposed to 1 μM iAsIII.
Changes in the pathways associated with cell cycle regulation were unique for UROtsa/F35
cells at this exposure level. The exposure of UROtsa cells to 50 μM iAsIII was characterized
by major effects on pathways regulating metabolism, followed by pathways associated with
transcription, cell death, and cell cycle. Pathways regulating metabolism and cell deaths
were also affected in UROtsa/F35 cells exposed to 50 μM iAsIII. However, alterations in
pathways involved in cell growth, signaling, and cell adhesion were unique for this cell line
under these exposure conditions.
Strain effects on functional gene categories
Further analyses focused only on effects of the sub-toxic exposure to 1 μM iAsIII, as this
concentration is relevant for chronic environmental exposures to iAs. We utilized the Venn
analysis displayed in Figure 4A to identify genes uniquely associated with UROtsa (96
genes) or UROtsa/F35 cells (24 genes) exposed to 1 μM iAs. Mapping such small numbers
of genes to pathways did not yield meaningful results. Therefore, we focused on
examination of functional clusters of genes contained within these lists. We mapped the
gene lists to DAVID Bioinformatic software to find any highly related genes and their
annotations to understand the common biology among related genes. The results are
presented in Table 4a,b and Figures 6A and 6B. The functional clusters of genes associated
with methylating UROtsa/F35 exposed to 1 μM iAs (Figure 6A) are involved in
chromosome stability, DNA synthesis, and cell cycle as compared to non-methylating
UROtsa cells (Figure 6B) that showed a gene cluster of metallothioneins, proteins with a
high content of cysteine residues that bind various heavy metals.
Discussion
It has been generally recognized that the enzymatic methylation of iAs is one of the key
factors that determine outcomes of acute and chronic exposures to iAs. Methylated
arsenicals containing AsIII (MAsIII and DMAsIII) are more toxic than iAs species in animal
and cell culture models8,15,16 and are more potent than iAs as genotoxins, inhibitors of
several redox enzymes, and modulators of major signal transduction pathways in
mammalian cells.7,17,18 At low sub-micromolar levels, both iAsIII and methylated trivalent
arsenicals induce production of inflammatory and growth promoting cytokines and cell
proliferation.19 Chronic exposures to low micromolar concentrations of iAsIII have been
shown to induce malignant transformation in human cells that lack As methylation
activity,20 indicating that methylation is not required for iAs to produce malignant
phenotype. However, recent studies showed that in UROtsa cultures, malignant
transformation can be induced by either iAsIII or MAsIII. Notably, the concentration that
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transformed UROtsa cells to malignant phenotype was much lower for MAsIII (0.05 μM)21
as compared to iAsIII (1 μM).22
Changes in gene expression associated with exposures to iAs have been extensively studied
in both animal and cell culture models. However, little is known about the role of
methylation in modulation of the effects of iAs exposure on gene expression. Su and
associates23 have recently examined gene expression profiles in non-tumorigenic SV-40-
transformed human urothelial (HUC-1) cells chronically exposed to iAsIII, MAsIII, or
DMAsIII. Their results show that gene expression profiles in iAsIII-treated cells closely
resemble those found in tumorigenic HUC-1 cells generated by treatment with
methylcholanthrene. Notably, effects of MAsIII, and particularly of DMAsIII, on gene
expression differed significantly from the effects of iAsIII. In our study, effects of iAsIII on
gene expression pattern were examined in UROtsa cells that lack As methylation activity
and in UROtsa/F35 cells that acquired this activity after stable expression of AS3MT. Thus,
instead of examining the effects of individual arsenicals, this study evaluates effects of a
mixture of natural metabolites of iAs produced by the AS3MT-catalyzed reactions and
distributed between the cells and the extracellular compartment in a manner that may be
consistent with in vivo processes in tissues methylating iAs or tissues that do not express
AS3MT, but are exposed to methylated metabolites produced elsewhere.
In this study, we chose to examine effects of two iAsIII concentrations: 1 and 50 μM. The
metabolism and cytotoxicity of iAsIII in UROtsa and UROtsa/F35 cultures exposed to these
concentrations have been characterized in details in our previous report.11 Briefly, we have
shown that a 24-h exposure to 1 μM iAsIII had no effect on viability of either UROtsa or
UROtsa/F35 cells. In contrast, exposure to 50 μM iAsIII decreased viability of UROtsa or
UROtsa/F35 cells by about 10 and 30%, respectively. Therefore, we refer to 1 μM iAsIII as
the “non-toxic” or “subtoxic” concentration and 50 μM iAsIII as the “cytotoxic”
concentration. Results of this study suggest that gene expression profiles in cells exposed to
iAsIII depend strongly on the concentration of iAsIII in culture and on the presence of
AS3MT activity. Consistent with these findings, the exposure to the cytotoxic concentration
of 50 μM iAsIII produced far more extensive changes in gene expression pattern than
exposure to the subtoxic concentration of 1 μM iAsIII. Given the numbers of genes affected,
the effects of the subtoxic concentration of 1 μM iAsIII were less pronounced in methylating
UROtsa/F35 as compared to parent UROtsa cells (Figure 4). Under these conditions, iAsIII
was effectively methylated, yielding almost exclusively DMAs (Figure 1). Thus, at this
exposure level, the efficient conversion of iAsIII to DMAs might play a detoxification role,
limiting the immediate effects of iAsIII and particularly effects of the highly reactive
intermediary metabolite, MAsIII, on gene expression. Notably, significant changes in
expression of genes regulating cell cycle in UROtsa/F35 cells exposed to 1 μM iAsIII
(Figure 5A) are consistent with previously reported proliferative effects of low, sub-
micromolar concentrations of trivalent arsenicals, specifically MAsIII and DMAsIII.19
In general, 24-h exposures to 1 μM iAsIII had little effect on gene expression pattern and
pathways in either parent UROtsa or UROtsa/F35 cells. However, examination of potential
functional clusters of genes revealed specific responses associated with the presence or
absence of AS3MT activity. Exposure to 1 μM iAsIII significantly altered a cluster of genes
involved in chromosomal stability, DNA synthesis, and cell cycle in methylating UROtsa/
F35 cells (Figure 6). These alterations are consistent with malignant transformation of
UROtsa cells by chronic exposures to very low concentrations of MAsIII described by
Bredfeldt and associates.21 In contrast, in non-methylating UROtsa cells, exposure to 1 μM
iAsIII affected a cluster of genes regulating expression of metallothioneins (Figure 6B).
Zhou and associates have shown that malignant transformation of UROtsa cells by exposure
to iAs is associated with an increased expression of metallothionein.24 Binding of iAs to
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cysteine-rich domains in the molecule of metallothionin is thought to contribute to
detoxification of iAs in mammalian cells.25,26 Effects of methylated metabolites of iAs on
metallothionein expression or effects of metallothionein on toxicity of methylated arsenicals
have not been examined.
Unlike the exposure to subtoxic 1 μM iAsIII, exposure to cytotoxic 50 μM iAsIII has more
pronounced effects on methylating cells; twice as many genes in UROtsa/F35 were affected
as compared to UROtsa cells (Figure 3B). Consistent with previous reports,5,27 high
concentration of iAsIII in UROtsa/F35 culture inhibited As methylation activity, specifically
DMAs formation; MAs was the major methylated metabolite found both in cells and culture
medium (Figure 2). Thus, the pronounced effects of 50 μM iAsIII in UROtsa/F35 cells,
particularly the specific effects on genes associated with cell adhesion, cell growth, and
signaling (Figure 5B) can be at least in part attributed to MAs production. These data are in
a good agreement with results of our previous study that linked the increased susceptibility
of UROtsa/F35 cells to acute toxicity of iAs with formation and accumulation of MAs,
specifically MAsIII.11 Taken together, accumulation of MAsIII and the MAsIII-induced
changes in gene expression may contribute in a significant way to toxicity of acute
exposures to high concentrations/doses of iAs that inhibit AS3MT-catalyzed production of
DMAs, thus impairing the capacity of cells to detoxify iAs. However, it is possible that high
concentrations of iAs in tissues may also result from chronic environmental or occupation
exposures to high levels of iAs in environmental media, particularly, in individuals with
impaired capacity to methylate iAs due to liver disease or due to AS3MT polymorphisms
that favor MAs production.
In summary, results of the present study provide additional evidence for an important role of
AS3MT-catalyzed methylation in modulation of iAs toxicity. More research will be needed
to dissect the effects of iAs exposure on specific clusters of genes and pathways in
methylating cells and in cells lacking the As methylation activity and to link these effects to
specific toxicities associated with acute and chronic exposures to iAs.
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Distribution of As species in UROtsa and UROtsa/F35 cultures exposed to 1 μM
[73As]iAsIII for 24 h. The average concentrations of iAs, MAs, and DMAs are shown for n =
3.
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Distribution of As species in UROtsa and UROtsa/F35 cultures exposed to 50 μM
[73As]iAsIII for 24 h. The average concentrations of iAs, MAs, and DMAs are shown for n =
3.
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Results of the principal component analysis of variability of gene expression in UROtsa and
UROtsa/35 cells before and after exposure to 1 or 50 μM iAsIII.
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Venn analysis of statistically filtered genes in UROtsa and UROtsa/F35 cells exposed to 1
μM iAsIII (A) and 50 μM iAsIII (B).
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Changes in pathway distribution in UROtsa and UROtsa/F35 cells. The pathways most
significantly affected by exposures to 1 μM iAsIII (A) and 50 μM iAsIII (B).
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Gene clusters uniquely associated with UROtsa cells (A) and UROtsa/F35 cells (B) exposed
to 1 μM iAsIII.
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Table 1a
Effects of UROtsa genotype exposed to 1 μM iAs at the pathway level
Pathway P-Value No. of genes expressed No. of genes in pathway Percentage (%)
Cell adhesion
 ECM remodeling 4.44E-05 5 60 8
 Chemokines and adhesion 4.88E-02 4 209 2
Carbohydrate metabolism
 Pentose phosphate pathway 4.25E-03 2 15 13
 Glycolysis and gluconeogenesis p. 1 6.80E-03 2 19 11
 Fructose metabolism 1.76E-02 2 31 6
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Table 1b
Effects of UROtsa/F35 genotype exposed to 1 μM iAs at the pathway level
Pathway P-Value No. of genes expressed No. of genes in pathway Percentage (%)
Cell cycle control
 Start of DNA replication in early S phase 1.12E-06 4 43 9
 Transition and termination of DNA replication 4.03E-05 3 36 8
 ATM/ATR regulation of G1/S checkpoint 2.82E-03 2 42 5
 Chromosome condensation in prometaphase 2.95E-03 2 43 5
 Sister chromatid cohesion 3.23E-03 2 45 4
Nucleotide metabolism
 TTP metabolism 2.19E-03 2 37 5
 dCTP/dUTP metabolism 2.82E-03 2 42 5
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Table 2a
Effects of UROtsa genotype exposed to 50 μM iAs at the pathway level
Pathway P-Value No. of genesexpressed
No. of genes in
pathway Percentage (%)
Cell cycle control
 Sister chromatid cohesion 2.24E-02 5 45 11
Cell death/Apoptosis
 TNFR1 signaling pathway 2.44E-02 5 46 11
 Caspase cascade activation by FADD and RIPK proteins 3.00E-02 4 33 12
Regulation of transcription
 Role of heterochromatin protein 1 (HP1) family in
transcriptional silencing
4.16E-02 5 53 9
 Formation of Sin3A and NuRD complexes and their role
in transcription regulation
4.77E-02 5 55 9
Function groups/kinases
 MAPK signaling cascade. Activation of MSK 1.33E-02 4 26 15
Metabolism—amino acid
 Proline metabolism 1.73E-02 4 28 14
 TCA 3.38E-02 3 20 15
 Arginine metabolism 4.71E-02 4 38 11
Metabolism—lipid
 Globo-(isoglobo) series GSL metabolism 1.84E-02 3 16 19
 Ganglioside Metabolism 4.83E-02 2 10 20
Metabolism of mediators
 Polyamine metabolism 8.60E-03 4 23 17
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Table 2b
Effects on pathways due to Urotsa/F35 genotype exposed to 50 μM iAs
Pathway P-Value No. of genes
expressed




 FAK signaling 1.57E-03 13 70 19
 Ephrins signaling 2.47E-02 9 58 16
 Reverse signaling by ephrin B 4.31E-02 11 84 13
Cell death/Apoptosis
 BAD phosphorylation 1.94E-02 12 84 14
 Cytoplasm/mitochondrial transport of proapoptotic proteins Bad
and Bax
3.14E-02 8 51 16
Growth and differentiation
 Angiotensin activation of ERK 5.09E-02 8 56 14
 Putative erythropoietin signaling pathway 1.26E-02 9 52 17
 Putative erythropoietin signaling pathway 3.40E-02 10 71 14
 FGF-family signaling 3.55E-02 6 34 18
 PIP3 signaling in 9.08E-03 12 76 16
 GDNF signaling 8.19E-03 6 25 24
Immune response
 Signaling pathway mediated by IL-6 and IL-1 1.44E-02 7 36 19
 IL6 signaling pathway 2.71E-02 6 32 19
 IL22 signaling pathway 2.80E-02 5 24 21
 BCR pathway 4.98E-02 11 86 13
Regulation of transcription
 Receptor-mediated HIF regulation 2.50E-02 7 40 18
 Transcription factor Tubby signaling pathways 3.19E-02 7 42 17
Cyto/chemokines
 CXCR4 signaling pathway 1.63E-03 11 54 20
 CXCR4 signaling via second messenger 4.24E-02 8 54 15
G-proteins/GPCR
 A2BR signaling via G-beta/gamma dimer. RGS and CaM-related
GIRK regulation
1.00E-02 6 26 23
 G-Protein alpha-q signaling cascades 1.02E-02 10 59 17
 G-Protein beta/gamma signaling cascades 1.60E-02 9 54 17
 Membrane trafficking and signal transduction of G-alpha (i)
heterotrimeric G-protein
1.67E-02 7 37 19
 G-Protein alpha-i signaling cascades 2.82E-02 8 50 16
 Rhodopsin phototransduction cascade in retina - the key role of
Ca2+ transport
3.32E-02 9 61 15
 A2BR signaling via G-alpha-q: PRKCA - RSK & JNK specific
pathways
3.85E-02 8 53 15
 G-Protein alpha-12 signaling pathway 3.85E-02 8 53 15
 CDC42 in cellular processes 1.01E-02 12 77 16
 CREB pathway 1.15E-02 16 117 14
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Pathway P-Value No. of genes
expressed
No. of genes in
pathway
Percentage (%)
 RAN regulation pathway 1.20E-02 8 43 19
Function groups/kinases
 MAPK cascade. Part II, Map 2 - MAP4K2-4 - ERK/JNK pathway;
interaction with MEK1/2
1.57E-03 10 46 22
 MAPK cascade. Part II, Map 3 - MAP4K2-4 - JNK/ERK5
pathway. Interaction with P-38 Cascade
2.34E-02 6 31 19
 MAPK cascade. Part I. Map 1. ERK-related pathways 3.48E-02 8 52 15
 Role PKA in cytoskeleton reorganization 3.70E-02 11 82 13
Function groups/second messenger
 Pleckstrin homology proteins interactions 3.83E-02 5 26 19
Metabolic maps/Nucleotide metabolism
 GTP-XTP metabolism 2.74E-02 9 59 15
Regulation of metabolism
 Insulin receptor signaling pathway 3.58E-02 7 43 16
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Table 3a
Effects on pathways by 1 μM iAs
Pathway P-Value No. of genes
expressed




 Plasmin signaling 5.38E-02 1 47 2
Growth and differentiation
 VEGF signaling via VEGFR2—generic cascades 4.93E-02 1 43 2
Immune response
 IFN alpha/beta signaling pathway 3.47E-02 1 30 3
Transcription factors
 Role of AP-1 in regulation of cellular metabolism 4.93E-02 1 43 2
Amino acid metabolism
 Methionine-cysteine-glutamate metabolism 2.09E-02 1 18 6
Lipid metabolism
 LDL metabolism during development of fatty streak lesion 2.20E-02 2 199 1
Vitamin and cofactor metabolism
 Glutathione metabolism 7.83E-04 2 36 6
 Heme metabolism 4.60E-02 1 40 3
Regulation of metabolism
 Transcription regulation of amino acid metabolism 4.82E-02 1 42 2
 RhoA regulation pathway (extension, GEFs/GAPs) 3.92E-02 1 34 3
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Table 3b
Effects of 50 μM iAs at the pathway level
Pathway P-Value No. of genes
expressed




 Chemokines and adhesion 1.35E-05 57 209 27
 TGF, WNT and cytoskeletal remodeling 3.16E-05 55 205 27
 Cytoskeleton remodeling 4.11E-05 49 178 28
 Integrin outside-in signaling 1.20E-04 26 79 33
 Fibronectin-binding integrins in cell motility 5.00E-03 16 52 31
 Integrin-mediated cell adhesion 9.74E-03 24 94 26
Cell cycle control
 Chromosome condensation in prometaphase 1.84E-09 24 43 56
 Sister chromatid cohesion 6.29E-09 24 45 53
 Start of the mitosis 3.24E-08 27 58 47
 Brca1 as transcription regulator 4.34E-08 18 30 60
 Start of DNA replication in early S phase 4.00E-07 21 43 49
 Transition and termination of DNA replication 1.75E-06 18 36 50
 ATM/ATR regulation of G1/S checkpoint 2.64E-05 18 42 43
 Role of Brca1 and Brca2 in DNA repair 3.38E-05 17 39 44
 Role APC in cell cycle regulation 3.41E-05 21 54 39
 Role SCF complex in cell cycle regulation 5.02E-05 17 40 43
 DNA-damages-induced responses 6.47E-05 7 9 78
 ATM/ATR regulation of G2/M checkpoint 1.30E-04 13 28 46
 The metaphase checkpoint 2.61E-04 15 37 41
 Regulation of G1/S transition 7.48E-04 20 61 33
 Spindle assembly and chromosome separation 3.89E-03 23 83 28
 Cell cycle (generic schema) 4.18E-03 9 22 41
 Role of NFBD1 in DNA damage response 5.99E-03 6 12 50
Cell death/Apoptosis
 Caspases cascade 3.41E-06 17 34 50
 Caspases cascade activation by granzyme and other signaling
proteins
2.14E-05 15 31 48
 Antiapoptotic Function of TRADD/TRAF2 complex 3.44E-05 15 32 47
 FAS signaling cascades. Part 2 1.48E-04 17 43 40
 TNFR1 signaling pathway 3.85E-04 17 46 37
 Caspases activation via nuclear import 3.92E-04 12 27 44
 Role of IAP-proteins in apoptosis 6.87E-04 14 36 39
 p53-dependent apoptosis 9.20E-04 13 33 39
 Cytoplasm/mitochondrial transport of proapoptotic proteins Bid,
Bmf, and Bim
1.74E-03 13 35 37
 TRAF proteins signaling network 1.74E-03 13 35 37
 p38-MAPK cascade activation via FAS1 and TNFR1 2.32E-03 11 28 39
 DNA-damages-induced apoptosis 4.81E-03 7 15 47
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Pathway P-Value No. of genes
expressed
No. of genes in
pathway
Percentage (%)
 Caspase cascade activation by FADD and RIPK proteins 9.82E-03 11 33 33
Growth and differentiation
 EGF signaling pathway 8.49E-03 18 64 28
 Estrogen receptor signaling pathway 3.44E-04 14 34 41
 Notch Signaling Pathway 5.19E-03 13 39 33
 PDGF signaling via STATs and NF-κB 6.60E-03 13 40 33
 IGF-RI signaling 6.64E-03 20 72 28
 Receptors. Part B. INSR—pleckstrin homology proteins
interactions
7.13E-03 12 36 33
 Receptors. Part E. EPOR - pleckstrin homology proteins
interactions
9.07E-03 12 37 32
Immune response
 IL9 signaling pathway 9.82E-03 11 33 33
 Regulation of transcription
 Formation of Sin3A and NuRD complexes and their role in
transcription regulation
4.83E-04 19 55 35
 Role of heterochromatin protein 1 (HP1) family in transcriptional
silencing
2.38E-03 17 53 32
 RalA regulation pathway 1.74E-03 13 35 37
 Regulation of CDC42 activity 8.17E-03 9 24 38
Function groups/kinases
 MAPK signaling cascade. Activation of MSK 4.36E-03 10 26 38
Function groups/phosphotases
 PTEN pathway 9.03E-03 16 55 29
Second messenger
 Receptors. Part F. KIT-pleckstrin homology (PH) proteins
interactions
4.23E-03 12 34 35
 PH proteins participation in RTKs adaptor complexes formation
and intermediation with focal adhesion complex. Part 2
8.49E-03 18 64 28
 PH proteins participation in different RTKs adaptor complexes
formation and intermediation with focal adhesion complex. Part 1
1.01E-02 18 65 28
Transcription factors
 Regulation of lipid metabolism via LXR, NF-Y and SREBP 5.53E-03 12 35 34
Nucleotide metabolism
 CTP/UTP metabolism 8.40E-05 23 65 35
 ATP/ITP metabolism 1.36E-04 24 71 34
 dCTP/dUTP metabolism 3.81E-04 16 42 38
 GTP-XTP metabolism 4.60E-04 20 59 34
 dATP/dITP metabolism 1.48E-03 17 51 33
 TTP metabolism 3.09E-03 13 37 35
 dGTP metabolism 6.60E-03 13 40 33
Steroid metabolism
 Cholesterol Biosynthesis 1.11E-04 11 21 52
Vitamin and cofactor metabolism
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Pathway P-Value No. of genes
expressed
No. of genes in
pathway
Percentage (%)
 Ubiquinone metabolism 1.47E-05 25 67 37
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Table 4a
Functional gene cluster associated with methylating UROtsa/F35 cells exposed to 1 μM iAsIII
NM_004526 mcm2 minichromosome preservation deficient 2, mitotin (S. cerevisiae)
NM_002592 proliferating cell nuclear antigen
NM_005483 chromatin assembly factor 1, subunit a (p150)
NM_002689 polymerase (dna directed), alpha 2 (70 kDa subunit)
NM_003504 cdc45 cell division cycle 45-like (S. cerevisiae)













Hester et al. Page 27
Table 4b
Functional gene cluster associated with non-methylating UROtsa cells exposed to 1 μM iAsIII
NM_005953 metallothionein 2a
NM_175617 metallothionein 1e (functional)
NM_005947 metallothionein 1b (functional)
NM_005950, NM_176870 metallothionein 1g
NM_005952 metallothionein 1x
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